JP2011500717A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500717A5
JP2011500717A5 JP2010530121A JP2010530121A JP2011500717A5 JP 2011500717 A5 JP2011500717 A5 JP 2011500717A5 JP 2010530121 A JP2010530121 A JP 2010530121A JP 2010530121 A JP2010530121 A JP 2010530121A JP 2011500717 A5 JP2011500717 A5 JP 2011500717A5
Authority
JP
Japan
Prior art keywords
composition
compound
cancer
salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500717A (ja
JP5733744B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/080221 external-priority patent/WO2009052323A2/en
Publication of JP2011500717A publication Critical patent/JP2011500717A/ja
Publication of JP2011500717A5 publication Critical patent/JP2011500717A5/ja
Application granted granted Critical
Publication of JP5733744B2 publication Critical patent/JP5733744B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530121A 2007-10-16 2008-10-16 凝血因子ＶＩＩａモジュレーターの製造、組成物及び使用 Active JP5733744B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98038607P 2007-10-16 2007-10-16
US60/980,386 2007-10-16
PCT/US2008/080221 WO2009052323A2 (en) 2007-10-16 2008-10-16 Manufacture, compositions and uses of coagulationfactor viia modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015078702A Division JP2015157830A (ja) 2007-10-16 2015-04-07 凝血因子ＶＩＩａモジュレーターの製造、組成物及び使用

Publications (3)

Publication Number Publication Date
JP2011500717A JP2011500717A (ja) 2011-01-06
JP2011500717A5 true JP2011500717A5 (enExample) 2011-11-17
JP5733744B2 JP5733744B2 (ja) 2015-06-10

Family

ID=40568072

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010530121A Active JP5733744B2 (ja) 2007-10-16 2008-10-16 凝血因子ＶＩＩａモジュレーターの製造、組成物及び使用
JP2015078702A Pending JP2015157830A (ja) 2007-10-16 2015-04-07 凝血因子ＶＩＩａモジュレーターの製造、組成物及び使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015078702A Pending JP2015157830A (ja) 2007-10-16 2015-04-07 凝血因子ＶＩＩａモジュレーターの製造、組成物及び使用

Country Status (9)

Country Link
US (3) US8552046B2 (enExample)
EP (2) EP2209801B1 (enExample)
JP (2) JP5733744B2 (enExample)
KR (1) KR20100093046A (enExample)
CN (2) CN103705507A (enExample)
CA (1) CA2702970A1 (enExample)
EA (2) EA201370191A1 (enExample)
ES (1) ES2403413T3 (enExample)
WO (1) WO2009052323A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
JP2008501700A (ja) 2004-06-02 2008-01-24 ファーマサイクリックス，インコーポレイティド 第ＶＩＩａ因子阻害剤
EP2209801B1 (en) 2007-10-16 2013-01-16 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulationfactor viia modulator
US20140046277A1 (en) * 2011-04-15 2014-02-13 Gamma Therapeutics, Inc. Fast-clotting wound dressings
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
EP2838566A2 (en) 2012-04-16 2015-02-25 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
WO2015003025A1 (en) * 2013-07-05 2015-01-08 Mousa Shaker A NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
AU2015325055B2 (en) * 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2641058C1 (ru) * 2016-11-17 2018-01-15 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ профилактики венозной тромбоэмболии у больных раком шейки матки
CN109627218B (zh) * 2018-11-27 2022-03-29 深圳市龙华区中心医院 一种抗凝小分子化合物及其应用和包含其的药物
CN116283896B (zh) * 2022-09-07 2024-10-29 广东晨康生物科技有限公司 一种具有pd-l1抑制活性的联苯类化合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
RU2093176C1 (ru) * 1992-12-16 1997-10-20 Левон Никитович Мкртчян Способ лечения рака молочной железы и рака тела матки
PL349192A1 (en) * 1998-12-18 2002-07-01 Axys Pharmaceuticals Protease inhibitors
US6465503B2 (en) 2000-08-11 2002-10-15 Axys Pharmaceuticals, Inc. Selective urokinase inhibitors
US20020037912A1 (en) 2000-08-11 2002-03-28 Leahy Ellen M. Factor viia inhibitors
ES2268539T3 (es) * 2001-03-23 2007-03-16 Novo Nordisk A/S Canula de aguja.
CA2452391A1 (en) 2001-07-09 2003-01-23 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
EP1569912B1 (en) * 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
CA2474195A1 (en) * 2002-02-13 2003-08-21 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
EP1492544A4 (en) * 2002-04-08 2005-10-12 Guilford Pharm Inc PHARMACEUTICAL COMPOSITIONS CONTAINING PROPOFOL-BASED WATER-SOLUBLE PRODRUGS AND METHODS OF ADMINISTRATION THEREOF
WO2004062661A1 (en) * 2003-01-08 2004-07-29 Axys Pharmaceuticals, Inc. 2-‘5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
JP2008501700A (ja) * 2004-06-02 2008-01-24 ファーマサイクリックス，インコーポレイティド 第ＶＩＩａ因子阻害剤
JP2008501702A (ja) * 2004-06-02 2008-01-24 ファーマサイクリックス，インコーポレイティド 第ＶＩＩａ因子阻害剤
EP2209801B1 (en) 2007-10-16 2013-01-16 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulationfactor viia modulator
US20110299806A1 (en) * 2010-06-08 2011-12-08 Leonid Kashchenevsky Spindle, shaft supporting device and method of supporting a rotatable shaft

Similar Documents

Publication Publication Date Title
JP2011500717A5 (enExample)
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
US20090227633A1 (en) Methods to inhibit tumor cell growth by using proton pump inhibitors
HRP20160014T1 (hr) Derivati 1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamida kao inhibitori fosfatidilinozitol 3-kinaze (pi3k), koji su korisni u lijeäśenju proliferativnih bolesti
RU2015106524A (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ ИНГИБИТОРА CDK4/6 И ИНГИБИТОРА В-Raf
JP2020514311A5 (enExample)
JP2013501224A5 (enExample)
RU2010151952A (ru) Водорастворимые аналоги ацетаминофена
JP2016006096A5 (enExample)
JP2009536191A5 (enExample)
RU2015125307A (ru) Комбинированная терапия
JP2015536964A5 (enExample)
JP2017526662A5 (enExample)
JP2020097577A5 (enExample)
JP2011518202A5 (enExample)
RU2011124894A (ru) Триазолотиадиазоловый ингибитор протеинкиназы с-мет
TNSN07419A1 (en) Methods for treating drug resistant cancer
WO2012117257A8 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
JP2006519852A5 (enExample)
JP2012522841A5 (enExample)
AU2018206479B2 (en) Inhibitors of NHE-mediated antiport
RU2014112108A (ru) Составы с производными децитабина
JP2019511550A5 (enExample)
JP2016527202A5 (enExample)
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib